157 related articles for article (PubMed ID: 36435920)
1. Identification of eIF6 as a prognostic factor that drives tumor progression and predicts arsenic trioxide efficacy in lung adenocarcinoma.
Shen Y; Zhang R; Li X
Mol Biol Rep; 2023 Feb; 50(2):1167-1180. PubMed ID: 36435920
[TBL] [Abstract][Full Text] [Related]
2. Actin-like protein 8 promotes cell proliferation, colony-formation, proangiogenesis, migration and invasion in lung adenocarcinoma cells.
Ma S; Wang X; Zhang Z; Liu D
Thorac Cancer; 2020 Mar; 11(3):526-536. PubMed ID: 31962007
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-147b promotes lung adenocarcinoma cell aggressiveness through negatively regulating microfibril-associated glycoprotein 4 (MFAP4) and affects prognosis of lung adenocarcinoma patients.
Feng YY; Liu CH; Xue Y; Chen YY; Wang YL; Wu XZ
Gene; 2020 Mar; 730():144316. PubMed ID: 31884109
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CENPF is associated with progression and poor prognosis of lung adenocarcinoma.
Li MX; Zhang MY; Dong HH; Li AJ; Teng HF; Liu AL; Xu N; Qu YQ
Int J Med Sci; 2021; 18(2):494-504. PubMed ID: 33390818
[No Abstract] [Full Text] [Related]
5. Arsenic trioxide elicits anti-tumor activity by inhibiting polarization of M2-like tumor-associated macrophages via Notch signaling pathway in lung adenocarcinoma.
Yin JZ; Shi XQ; Wang MD; Du H; Zhao XW; Li B; Yang MH
Int Immunopharmacol; 2023 Apr; 117():109899. PubMed ID: 36827926
[TBL] [Abstract][Full Text] [Related]
6. Histone lysine methyltransferase SETDB2 suppresses NRF2 to restrict tumor progression and modulates chemotherapy sensitivity in lung adenocarcinoma.
Yuan G; Hu B; Ma J; Zhang C; Xie H; Wei T; Yang Y; Ni B
Cancer Med; 2023 Mar; 12(6):7258-7272. PubMed ID: 36504353
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma.
Zhong Y; Jiang L; Lin H; Li X; Long X; Zhou Y; Li B; Li Z
IUBMB Life; 2019 Jul; 71(7):942-955. PubMed ID: 30817091
[TBL] [Abstract][Full Text] [Related]
8. CCNE1 Promotes Progression and is Associated with Poor Prognosis in Lung Adenocarcinoma.
Ma G; Yang L; Dong J; Zhang L
Curr Pharm Biotechnol; 2022; 23(9):1168-1178. PubMed ID: 34792009
[TBL] [Abstract][Full Text] [Related]
9. KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A.
Zhao W; Xie Y
Pathol Res Pract; 2021 Jan; 217():153284. PubMed ID: 33249400
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of PELP1 in Lung Adenocarcinoma Promoted E
Zhang D; Dai J; Pan Y; Wang X; Qiao J; Sasano H; Zhao B; McNamara KM; Guan X; Liu L; Zhang Y; Chan MSM; Cao S; Liu M; Song S; Wang L
Pathol Oncol Res; 2021; 27():582443. PubMed ID: 34257530
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of lncRNA A2M-AS1 inhibits cell growth and aggressiveness
Guo H; Li T; Peng C; Mao Q; Shen B; Shi M; Lu H; Xiao T; Yang A; Liu Y
Hum Exp Toxicol; 2022; 41():9603271221138971. PubMed ID: 36461613
[TBL] [Abstract][Full Text] [Related]
12. Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma.
Hao XL; Tian Z; Han F; Chen JP; Gao LY; Liu JY
Pathol Res Pract; 2019 Jul; 215(7):152438. PubMed ID: 31126818
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
14. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma.
Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X
Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692
[TBL] [Abstract][Full Text] [Related]
15. LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/ glycolysis axis in lung adenocarcinoma.
Chen Z; Hu Z; Sui Q; Huang Y; Zhao M; Li M; Liang J; Lu T; Zhan C; Lin Z; Sun F; Wang Q; Tan L
Int J Biol Sci; 2022; 18(2):522-535. PubMed ID: 35002507
[No Abstract] [Full Text] [Related]
16. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
Zhu HE; Yin JY; Chen DX; He S; Chen H
Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
[TBL] [Abstract][Full Text] [Related]
17. CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma.
He J; Lan X; Liu X; Deng C; Luo H; Wang Y; Kang P; Sun Z; Zhao L; Zhou X
BMC Cancer; 2023 Mar; 23(1):266. PubMed ID: 36959566
[TBL] [Abstract][Full Text] [Related]
18. GPR37 promotes cancer growth by binding to CDK6 and represents a new theranostic target in lung adenocarcinoma.
Xie X; Cai X; Zhou F; Li Y; Liu Q; Cai L; Zhu W; Wei J; Jin C; Liu Z; Jiang C; Zhao H; Yang L; Zhao C; Huang X
Pharmacol Res; 2022 Sep; 183():106389. PubMed ID: 35934193
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of BCCIP predicts an unfavorable prognosis and promotes the proliferation and migration of lung adenocarcinoma.
Shi J; Lv X; Li W; Ming Z; Zeng L; Yuan J; Chen Y; Liu B; Yang S
Thorac Cancer; 2021 Sep; 12(17):2324-2338. PubMed ID: 34297484
[TBL] [Abstract][Full Text] [Related]
20. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
